Ascendis Pharma A/S to Present at Three Upcoming Investor Conferences
COPENHAGEN, Denmark, Sept. 3, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced plans to present at several upcoming investor conferences.
| Event: |
2015 Wells Fargo Healthcare Conference in Boston |
||
| Date: |
Thursday, September 10, 2015 |
||
| Time: |
1:55pm EDT |
||
| Event: |
Bank of America Merrill Lynch Global Healthcare Conference in London |
||
| Date: |
Wednesday, September 16, 2015 |
||
| Time: |
11:25am GMT+1 |
||
| Event: |
Leerink Partners Rare Disease Roundtable in New York |
||
| Date: |
Wednesday, September 30, 2015 |
||
| Time: |
12:30pm EDT |
||
Links to audio webcasts of the conference presentations will be posted to the Ascendis Pharma website at www.ascendispharma.com when available.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of best-in-class therapeutics that address significant unmet medical needs. The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug.
The Ascendis Pharma pipeline includes TransCon Growth Hormone, a proprietary program that has completed Phase 2 studies in adults and children with growth hormone deficiency. Ascendis Pharma expects to initiate a Phase 3 pediatric study of TransCon Growth Hormone in mid-2016. Ascendis Pharma is also developing its wholly-owned TransCon Treprostinil for the treatment of pulmonary arterial hypertension. In addition to its proprietary programs, Ascendis Pharma has formed collaborations focused on leading products in large markets that are of strategic importance to its collaboration partners. These collaborations are with Sanofi in diabetes and Genentech in the field of ophthalmology.
Investor contact:
Martin Auster, M.D.
Chief Business Officer
(650) 617-3403
ir@ascendispharma.com
Logo - http://photos.prnewswire.com/prnh/20150824/260617LOGO
Share this article